Encapsulation of anticancer medications within liposomes is a technique to facilitate drug transportation to the target and accumulation in tumors. Sato and colleagues evaluated the tolerability and efficacy of a liposomal formulation of eribulin (E7389-LF) in patients with advanced solid tumors. E7389-LF was well tolerated overall, and 4/21 of the patients treated achieved a partial response. Endothelial cell, vasculature, and immune-related biomarkers were increased after treatment. Thus E7389-LF may influence tumor vascular remodeling. These findings support further evaluation of E7389-LF for advanced solid tumors. Expansion cohorts are ongoing to evaluate the safety, efficacy, and pharmacodynamics of E7389-LF 2.0 mg/m2 every 3 weeks in specific tumor types.

Molecular profiles in solid tumors dynamically evolve in response to endogenous and exogenous pressures. Lodrini and colleagues noninvasively monitored high-risk neuroblastoma evolution using droplet digital PCR assessing MYCN and ALK oncogene status in longitudinally collected biosamples to explore the clinical value of total...

You do not currently have access to this content.